14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYRE vs IONS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Ionis Pharmaceuticals, Inc. (IONS) on higher Unified Composite conviction (36.1/100 SELL vs. 60.4/100 BUY) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IONS wins 4–2 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus IONS at $28.57 (90.9x Forward P/E, -58.8% operating margin).
Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -58.8% operating margin) and revenue trajectory (+0.0% vs. +54.9% YoY).
Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs IONS. Trailing 12-month operating profitability (SYRE 0.0% vs IONS -58.8%) and valuation multiples (SYRE N/M vs IONS 90.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment61.8% of Rev ($593M)
90D Engineering Disclosures0 Published
Investor FAQ SYRE vs IONS Key Questions & Quantitative Answers
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Ionis Pharmaceuticals, Inc. (IONS) on higher Unified Composite conviction (36.1/100 SELL vs. 60.4/100 BUY) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while IONS wins 4–2 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.97 (N/M Forward P/E, 0.0% operating margin) versus IONS at $28.57 (90.9x Forward P/E, -58.8% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -58.8% operating margin) and revenue trajectory (+0.0% vs. +54.9% YoY). Technical & Structure Timing Caution: SYRE trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 56.6); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IONS leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IONS at +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $960M for IONS. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus 61.8% of Rev ($593M) (0 disclosures) for IONS.
IONS screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus IONS (-108.0% ROE) capital efficiency.
In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.